Process for the separation and purification of proteases and
antiproteases of blood clotting, as well as of the
protease/antiprotease complex
    102.
    发明授权
    Process for the separation and purification of proteases and antiproteases of blood clotting, as well as of the protease/antiprotease complex 失效
    用于分离和纯化血液凝固蛋白酶和抗蛋白酶的方法,以及蛋白酶/抗蛋白酶复合物

    公开(公告)号:US4945054A

    公开(公告)日:1990-07-31

    申请号:US495511

    申请日:1983-05-17

    摘要: The present invention relates to a process for separating and purifying proteases and antiproteases. This process is characterized in that there are placed in contact an insoluble cross-linked polymer including in its chain the group --SO.sub.3 R.sub.1 -- and/or the group --SO.sub.2 R.sub.2 -- in which R.sub.1 denotes a hydrogen atom or metal and R.sub.2 denotes the remainder of an amino acid linked to the --SO.sub.2 -- bridge through its amine --NH--, function, with the solution containing proteases and antiproteases or their complex; separating the polymer which has absorbed the desired protein, washing it carefully with the buffer, desorbing the absorbed protein by a solution of a polycationic compound in the case of T or by an albumin solution in the case of AT or of the complex T-AT, and isolating the protein, if desired, by known means, such as, especially, freeze drying. The invention is useful for studying the mechanism of blood coagulation.

    摘要翻译: 本发明涉及分离和纯化蛋白酶和抗蛋白酶的方法。 该方法的特征在于使不溶性交联聚合物与其中R1表示氢原子或金属的基团-SO3R1-和/或-SO2R2-基团在其链中相接触,R2表示其余的 氨基酸通过其氨基-NH-连接至-SO 2 - 桥键,与含有蛋白酶和抗蛋白酶或其复合物的溶液起作用; 分离吸收了所需蛋白质的聚合物,用缓冲液小心地洗涤,在T的情况下通过聚阳离子化合物的溶液或在AT或复合T-AT的情况下通过白蛋白溶液解吸所吸收的蛋白质 ,如果需要,通过已知的方法,特别是冷冻干燥来分离蛋白质。 本发明可用于研究凝血机制。

    Method of stimulating the growth of macrophage-like cells utilizing
mitogenic peptides
    104.
    发明授权
    Method of stimulating the growth of macrophage-like cells utilizing mitogenic peptides 失效
    利用促有丝分裂肽刺激巨噬细胞样细胞生长的方法

    公开(公告)号:US4704380A

    公开(公告)日:1987-11-03

    申请号:US928

    申请日:1987-01-07

    申请人: George D. Wilner

    发明人: George D. Wilner

    IPC分类号: C12N9/74 A61K37/02

    摘要: Novel tetradecapeptides having the following sequence were found to have potent mitogenic activity for machropage-like cells:H-Tyr-Pro-Pro-X-Asn-Lys-Asn-Phe-Thr-Glu-Asn-Asp-Leu-Leu-OH,wherein X=Trp or Tyr, or the physiologically acceptable salts, esters or amides thereof.

    摘要翻译: 发现具有以下序列的新型十四肽对于机械样细胞具有有效的促有丝分裂活性:H-Tyr-Pro-Pro-X-Asn-Lys-Asn-Phe-Thr-Glu-Asn-Asp-Leu-Leu-OH 其中X = Trp或Tyr,或其生理上可接受的盐,酯或酰胺。

    Method and composition for treating clotting factor inhibitors
    108.
    发明授权
    Method and composition for treating clotting factor inhibitors 失效
    用于治疗凝血因子抑制剂的方法和组合物

    公开(公告)号:US4357321A

    公开(公告)日:1982-11-02

    申请号:US262286

    申请日:1981-05-11

    申请人: William R. Thomas

    发明人: William R. Thomas

    摘要: A composition comprising about from 37 to 190 units of factor VII/ml and about from 25 to 80 units of factor VIIa/ml is administered to patients in the treatment of clotting factor inhibitors. The composition may include activated and unactivated clotting factors such as factors IX, IXa, Xa and X.

    摘要翻译: 在治疗凝血因子抑制剂时向患者施用包含约37至190单位因子VII / ml和约25至80单位因子VIIa / ml的组合物。 组合物可以包括活化和未活化的凝血因子,例如因子IX,IXa,Xa和X.

    Method for treating blood clotting factor inhibitors
    109.
    发明授权
    Method for treating blood clotting factor inhibitors 失效
    治疗凝血因子抑制剂的方法

    公开(公告)号:US4287180A

    公开(公告)日:1981-09-01

    申请号:US116186

    申请日:1980-01-28

    申请人: William R. Thomas

    发明人: William R. Thomas

    摘要: Compositions including, in units/ml, factor VIII correctional activity, about from 2-35; prothrombin, about from 1-10; thrombin, less than about 0.003; factor VII, about from 37-190; factor VIIa, about from 8-80; total factor IX, about from 15-112; factor IX precursor, 0 to about 30; factor X, about from 1-30; and factor Xa, about from 1-10 are used in therapeutically effective amounts to treat blood clotting factor inhibitors.

    摘要翻译: 组合物,以单位/ ml,因子VIII修复活性,约2-35; 凝血酶原,约1-10; 凝血酶,小于约0.003; 因子VII,约为37-190; 因子VIIa,约8-80; 总因子IX,约为15-112; 因子IX前体,0至约30; 因子X,约1-30; 约1-10个因子Xa以治疗有效量用于治疗凝血因子抑制剂。

    Fractionating citrate-stabilized plasma
    110.
    发明授权
    Fractionating citrate-stabilized plasma 失效
    分馏柠檬酸盐稳定的等离子体

    公开(公告)号:US4272523A

    公开(公告)日:1981-06-09

    申请号:US75867

    申请日:1979-09-17

    摘要: The present invention relates to a method for making fibrinogen, a prothrombin complex containing the coagulation factors II, VII, IX and X that can contain antithrombin III, antithrombin III and a solution of stable serum proteins from a blood plasma stabilized with citrate which is characterized in that from the plasma, by adsorption on colloidal silica of a specific surface of 50 to 400 m.sup.2 /g and a concentration of 50 to 400 mg per g plasma protein, fibrinogen is isolated; and in that thereupon (a) citrate and calcium ions are removed by ultrafiltration or dialysis and then from the protein solution, over anion exchangers or tricalcium phosphate that adsorb proteins, the coagulation factors II, VII, IX and X and antithrombin III are adsorbed, or (b) the coagulation factors II, VII, IX and X are adsorbed prior to the ultrafiltration or dialysis, antithrombin III then not being simultaneously adsorbed, and antithrombin III is adsorbed on the said adsorbents after the removal of the citrate and calcium ions by ultrafiltration or dialysis; and in that thereupon from the remaining plasma fluid further unstable proteins are removed by another adsorption on colloidal silica and a solution of stable serum proteins is obtained.

    摘要翻译: 本发明涉及一种制备纤维蛋白原的方法,一种含有凝血因子II,VII,IX和X的凝血酶原复合物,其可以含有抗凝血酶III,抗凝血酶III和用柠檬酸盐稳定的血浆中稳定的血清蛋白质的溶液, 从等离子体中,通过吸附比表面积为50〜400m2 / g,浓度为50〜400mg / g血浆蛋白质的胶体二氧化硅,分离纤维蛋白原; 因此(a)通过超滤或透析除去柠檬酸盐和钙离子,然后从蛋白质溶液中吸附蛋白质的阴离子交换剂或磷酸三钙,吸附凝血因子II,VII,IX和X以及抗凝血酶III, 或(b)凝血因子II,VII,IX和X在超滤或透析之前被吸附,抗凝血酶III然后不被同时吸附,并且在除去柠檬酸盐和钙离子之后,抗凝血酶III被吸附在所述吸附剂上 超滤或透析; 并且因此从剩余的血浆液体中,通过胶体二氧化硅上的另一种吸附除去进一步不稳定的蛋白质,并获得稳定的血清蛋白质的溶液。